References for Medical Providers
*A subscription to certain journals may be required to view full papers*
April 2015, Annals of Oncology
Utility of 18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.
February 2015, Annals of Oncology
Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center.
January 2013, Journal of Clinical Oncology
Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
September 2012, Journal of Clinical Oncology
Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.
August 2012, Clinical Lymphoma, Myeloma & Leukemia
(Cutaneous) Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.
June 2012, Journal of Clinical Oncology
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.
May 2012, Blood
(Cutaneous) Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.
February 2012, Journal of Clinical Oncology
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.
March 2011, Journal of Clinical Oncology
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
November 2010, Blood
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. http://www.ncbi.nlm.nih.gov/pubmed/20660290
July 2010, British Journal of Haematology
Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas.
May 2008, Journal of Clinical Oncology
Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire.
September 2007, Journal of Clinical Oncology
Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.
October 2014, Cancer Treatment Reviews
Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
June 2013, Therapeutic Advances in Hematology
Novel therapies for peripheral T-cell lymphomas.
March 2013, Best Practice & Research Clinical Haematology
Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.